Key player · Company profile
Amgen Inc.
Named as a key player in 231 of our reports, across 33 regions and countries.
Named as a key player in 231 of our reports, across 33 regions and countries.
2023–2033 CAGR · estimates
Australia 7
Brazil 7
Canada 7
China 7
Ecuador 7
Egypt 7
France 7
Germany 7
Hong Kong 7
India 7
Italy 7
Japan 7
Kenya 7
Malaysia 7
Mexico 7
New Zealand 7
Philippines 7
Russia 7
Saudi Arabia 7
Singapore 7
South Africa 7
Spain 7
Thailand 7
UAE 7
UK 7
US 7| Market | Category | World 2023 | CAGR |
|---|---|---|---|
| Biosimilars | Pharmaceuticals | $36.9 Bn | 24.9% |
| Over The Counter (OTC) Medications for Cough, Cold & Flu Drugs | OTC & Nutraceuticals | $14.5 Bn | 4.1% |
| Digital Biomarkers | Digital Health | $4.4 Bn | 35.5% |
| Bone Cancer Diagnostic | Healthcare Services | $1.1 Bn | 7.4% |
| Atherosclerosis Drugs | Pharmaceuticals | – | – |
| Axial Spondyloarthritis (axSpA) | Pharmaceuticals | – | – |
| Biosimilar Monoclonal Antibodies | Pharmaceuticals | – | – |
Named as key players in the same markets as Amgen Inc. (number of shared markets).
Novartis AG4 shared markets
Pfizer Inc.4 shared markets
Johnson & Johnson3 shared markets
AbbVie Inc.2 shared markets
AstraZeneca2 shared markets
Bayer AG2 shared markets
Biogen Inc2 shared markets
Bristol-Myers Squibb Company2 shared markets